Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

464
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
464

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to "The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing" [J. Liq. Biopsy 12 (2026) 100461].

The journal of liquid biopsy·2026
Same author

Evolving Landscape of Immunotherapy in Melanoma.

JCO oncology practice·2026
Same author

Clinicogenomic Features and Outcomes of Adenoid Cystic Carcinoma With Central Nervous System Metastases: A Single-Institution Cohort Study.

Head & neck·2026
Same author

Reporting of atrial fibrillation with bispecific T-cell engagers in the Food and Drug Administration Adverse Event Reporting System.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same author

Integrated Molecular and Clinical Analysis of Thymic Epithelial Tumors.

JCO precision oncology·2026
Same author

Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Advancing the Oncology Data Paradigm: Multisite Expansion of Structured Cancer Data Capture at the Point of Care.

JCO oncology practice·2026
Same journal

Clinical Research in Community Oncology: Advancing Cancer Care Through Localized Clinical Trials.

JCO oncology practice·2026
Same journal

Glucagon-Like Peptide-1 Receptor Agonists in Breast Cancer: Metabolic, Clinical, and Survivorship Implications.

JCO oncology practice·2026
Same journal

Implementation and Patient-Reported Outcomes of an Insurance-Supported Integrative Oncology Symptom Management Program.

JCO oncology practice·2026
Same journal

Implementing Systems-Based Interventions to Improve the Care of Cancer Survivors: Small Steps, Large Challenges.

JCO oncology practice·2026
Same journal

Patient Engagement With an Electronic Patient-Reported Outcomes Tool Evaluating Hospital Discharge Readiness After Cancer Surgery.

JCO oncology practice·2026
See all related articles

Related Experiment Video

Updated: May 28, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.0K

Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis.

Fauzia Riaz1, John L Vaughn2, Huili Zhu3

  • 1Stanford University School of Medicine, Stanford, CA.

JCO Oncology Practice
|February 12, 2025
PubMed
Summary
This summary is machine-generated.

Immune checkpoint inhibitors (ICIs) show poor outcomes in hospitalized patients. This study found limited survival benefit, suggesting cautious use of inpatient ICIs for cancer treatment.

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.2K
Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

23.1K

Related Experiment Videos

Last Updated: May 28, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.0K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.2K
Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

23.1K

Area of Science:

  • Oncology
  • Immunotherapy
  • Clinical Research

Background:

  • Immune checkpoint inhibitors (ICIs) have transformed cancer care.
  • Their use in hospitalized patients is debated due to uncertain benefits and high costs.

Purpose of the Study:

  • To evaluate the effectiveness and outcomes of immune checkpoint inhibitors (ICIs) administered in the inpatient setting.
  • To describe patient characteristics and survival following inpatient ICI treatment.

Main Methods:

  • Retrospective analysis of 215 patients receiving inpatient ICIs across five institutions (2012-2021).
  • Kaplan-Meier method for overall survival (OS) estimation.
  • Cox proportional hazards models to identify factors associated with OS.

Main Results:

  • Median OS was 1.55 months for all patients and 1.28 months for advanced solid malignancy cases.
  • Most patients (75%) were ICI-naïve with stage IV solid tumors.
  • No significant association found between clinicodemographic variables and improved OS.

Conclusions:

  • The Inpatient Immunotherapy Outcomes Study (IIOS) is the largest multi-institutional study on inpatient ICI outcomes.
  • Clinical outcomes following inpatient ICI administration are generally poor.
  • Inpatient immune checkpoint inhibitor use warrants careful consideration and cautious application.